Pfizer ups drug prices

Share this article:
Industry analysts say average wholesale prices for Pfizer drugs such as Lipitor and Celebrex went up by more than 5%, Reuters reported. A Bear Stearns analyst quoted in the report said the price hike, effective Jan. 1, was somewhat more aggressive than price increases taken in each of the previous three years. He estimated the rise at 5.2%; a Merrill Lynch analyst pegged it at 5.6%. While cholesterol drug Lipitor and arthritis therapy Celebrex were included in the increase, newer drugs Chantix (smoking cessation) and Exubera (diabetes) were not. The 5% boost surprised some analysts, who said they had anticipated a lesser increase in light of political scrutiny over drug pricing expected this year. However, one analyst added, Pfizer may have raised prices sharply to make good on its prediction that 2007 revenue will match that seen last year.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...